Jimmy K Limdi is an expert in Gastroenterology at University of Manchester (United Kingdom). As of October 2026, ScienceLeadR ranks Jimmy K Limdi in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Jimmy K Limdi has authored 335 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 1,339 (community average: 125). How the SLR is computed.

LeadR Profile

Jimmy K Limdi University of Manchester United Kingdom
1 339 ScienceLeadR Reputation 1339
Network Map

Gastroenterology

Subspecialties: Pharmacy - Hepatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

I am a Consultant Gastroenterologist and Head of the Inflammatory Bowel Disease Section at Northern Care Alliance NHS Foundation Trust (NE Sector) in Manchester, UK and Professor of Clinical Gastroenterology at the Manchester Academic Health Sciences Centre, University of Manchester. I am also Hon. Professor at the Manchester Metropolitan University and Deputy Director of Research &Innovation at the Northern Care Alliance NHS Foundation Trust, Manchester.

I qualified in 1993 and completed postgraduate training in Internal Medicine and Gastroenterology in Yorkshire and Manchester, followed by a period of research at the ICMS, Barts and The London, and University College Hospitals, London. My clinical research interests in IBD include translational research, clinical trials, IBD therapeutics, diet, gut permeability and nutriceuticals, early diagnosis and outcomes, IBD in older persons, neuromotility in IBD, exercise and IBD and women’s health related issues in IBD.

I am a Principal and Chief Investigator to several IBD studies, Associate Editor of the Inflammatory Bowel Diseases journal, Therapeutic Advances in Gastroenterology, Drugs Context and Frontline Gastroenterology. I hold Editorial board and peer review appointments with leading gastroenterology journals and have published and lectured widely in the field. I have participated in several national and international peer review processes, Delphi panels and co-authored national and international IBD guidelines. I was previously BSG representative to the Association of Coloproctologists of GB&I, the BSG Food and Function CRG and the UK National Representative at the American College of Gastroenterology (ACG) between 2012 and 2021.

I am currently a member of the World Congress of Gastroenterology IBD Committee, BSG IBD Committee, BSG IBD Section Representative to the BSG Education Committee, BSG Education Representative to the International Committee, BSG National representative to the Americas and The Caribbean and the UK National Representative to the ACG.




Organizations

Career arc: 2006 - 2026

Source: PubMed

National Health Service

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 335

Citations

Citations: 11 088 1st author: 30 Last author: 122 Unique author: 25


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.
PMID 42874103 — research design, interleukin-23, colitis, respect, drug-related side effects and adverse reactions, colitis, ulcerative
N Engl J Med Top journal20260
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
PMID 42426976 — quality of life, ustekinumab, safety, crohn disease, drug-related side effects and adverse reactions, pharmacology, therapeutics
Aliment Pharmacol Ther20260
Guselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning.
PMID 42739673 — interleukin-23, safety, inflammatory bowel diseases, therapeutics, colitis, ulcerative
J Clin Med20260
Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms.
PMID 42614656 — treatment outcome, pharmaceutical preparations, drug monitoring, drug elimination routes, inflammatory bowel diseases, therapeutics
Front Gastroenterol (Lausanne)20260
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
PMID 42413123 — colitis, inflammatory bowel diseases, therapeutics, colitis, ulcerative, small molecules
J Crohns Colitis20267

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 5
N/A 3
Phase 2 1

By status:

Completed 7
Active not recruiting 1
Unknown 1

By type:

Interventional 6
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 4

LeadR Networks

Main global connection map